ATE503186T1 - Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben - Google Patents

Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben

Info

Publication number
ATE503186T1
ATE503186T1 AT05731863T AT05731863T ATE503186T1 AT E503186 T1 ATE503186 T1 AT E503186T1 AT 05731863 T AT05731863 T AT 05731863T AT 05731863 T AT05731863 T AT 05731863T AT E503186 T1 ATE503186 T1 AT E503186T1
Authority
AT
Austria
Prior art keywords
situ
testic
cancer
detecting
derived cancers
Prior art date
Application number
AT05731863T
Other languages
English (en)
Inventor
Kristian Almstrup
Christina Hyi-Hansen
Meyts Ewa Rajpert-De
Ute Wirkner
Wilhelm Ansorge
Henrik Leffers
Niels Skakkebfk
Christian Schwager
Jonathon Blake
Original Assignee
Rigshospitalet Copenhagen University Hospital
Univ Copenhagen
Europ Molecular Biology Lab Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet Copenhagen University Hospital, Univ Copenhagen, Europ Molecular Biology Lab Heidelberg filed Critical Rigshospitalet Copenhagen University Hospital
Application granted granted Critical
Publication of ATE503186T1 publication Critical patent/ATE503186T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05731863T 2004-04-23 2005-04-21 Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben ATE503186T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400647 2004-04-23
DKPA200402032 2004-12-30
PCT/DK2005/000280 WO2005103703A2 (en) 2004-04-23 2005-04-21 Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples

Publications (1)

Publication Number Publication Date
ATE503186T1 true ATE503186T1 (de) 2011-04-15

Family

ID=34965534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05731863T ATE503186T1 (de) 2004-04-23 2005-04-21 Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben

Country Status (9)

Country Link
US (1) US20090298053A1 (de)
EP (3) EP2273271A3 (de)
JP (2) JP2007533311A (de)
AT (1) ATE503186T1 (de)
AU (1) AU2005236125C1 (de)
CA (1) CA2563917A1 (de)
DE (1) DE602005027065D1 (de)
DK (1) DK1747465T3 (de)
WO (1) WO2005103703A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022041A2 (en) * 2005-08-11 2007-02-22 Novartis Ag Mutations and polymorphisms of hdac3
JP5099535B2 (ja) * 2005-11-17 2012-12-19 独立行政法人産業技術総合研究所 Ｋａｎｋ４遺伝子の癌治療及び癌検出並びに創薬への利用
US20080241110A1 (en) * 2005-11-29 2008-10-02 Nevada Cancer Institute Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
EP2193465A1 (de) * 2007-08-29 2010-06-09 Genstruct, Inc. Computerunterstützte entdeckung von biomarkerprofilen in komplexen biologischen systemen
US20120021937A1 (en) * 2008-10-16 2012-01-26 Kobenhavns Universitet Detection of carcinoma in situ in semen specimens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147863A1 (en) * 2001-12-17 2003-08-07 Isis Pharmaceuticals Inc. Antisense modulation of TFAP2C expression
CN1703522A (zh) * 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
GB0307206D0 (en) * 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation

Also Published As

Publication number Publication date
WO2005103703A2 (en) 2005-11-03
US20090298053A1 (en) 2009-12-03
DK1747465T3 (da) 2011-07-11
CA2563917A1 (en) 2005-11-03
JP2007533311A (ja) 2007-11-22
EP2273271A3 (de) 2011-04-13
EP1747465A2 (de) 2007-01-31
AU2005236125C1 (en) 2011-09-22
EP2273271A2 (de) 2011-01-12
JP2011147456A (ja) 2011-08-04
WO2005103703A3 (en) 2006-07-13
DE602005027065D1 (de) 2011-05-05
AU2005236125B2 (en) 2011-06-02
EP1747465B1 (de) 2011-03-23
AU2005236125A1 (en) 2005-11-03
EP2083273A1 (de) 2009-07-29

Similar Documents

Publication Publication Date Title
HK1159249A1 (en) Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques
EP1842065A4 (de) Diagnose- und prognoseverfahren von epithelkrebs
GB0612649D0 (en) No title
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
IL211255A0 (en) Cop1 molecules and uses thereof
DE602007009645D1 (de) Reagenzien und verfahren für krebsprognose und pathologische einstufung
WO2006012646A3 (en) Amacr cancer markers
EP2177614A3 (de) Zusammensetzung und Verfahren zur Diagnose von Speiseröhrenkrebs sowie der Metastasierung von Speiseröhrenkrebs
ATE553382T1 (de) Verwendungen von krebsspezifischen glykanen
WO2009055820A3 (en) Salivary protein biomarkers for human oral cancer
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
WO2004060302A3 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2006125021A3 (en) Fibrinogen alpha and hemoglobin polypeptides as cancer markers
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
MXPA06012232A (es) Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.
ATE503186T1 (de) Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben
DK2199801T3 (da) Biomarkører til tidlig påvisning af ovariecancer
WO2007075672A3 (en) Prognostic cancer markers
MXPA05004971A (es) Pronostico para malignidad hematologica.
WO2002080844A3 (en) Novel bgp compounds for therapy and diagnosis and methods for using same
DE602004022632D1 (de) Verwendung von adiponectin zur diagnose von krebs
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
DE60320821D1 (de)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1747465

Country of ref document: EP